PMID- 19961892
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20100301
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 71
IP  - 3
DP  - 2010 Mar
TI  - Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics 
      of renal cell carcinoma patients.
PG  - 309-13
LID - 10.1016/j.humimm.2009.11.010 [doi]
AB  - Current evidence suggests that chronic inflammation is associated with tumor 
      development and progression. Interleukin-18 (IL-18) plays a central role in 
      inflammation and the immune response, contributing to the pathogenesis and 
      pathophysiology of infectious and inflammatory diseases. The objective of this 
      study was to determine whether the presence of IL-18 polymorphisms -137 G/C 
      (rs187238) and -607 A/C (rs1946518) was associated with size, grade, TNM stage, 
      and survival in patients with renal cell carcinoma (RCC). The study cohort 
      included 158 patients with RCC. Control group consisted of 506 samples from 
      Spanish population. The studied IL-18 gene polymorphisms did not influence 
      susceptibility to RCC in the analyzed group of patients (IL-18-607, p = 0.318; 
      IL-18-137 p = 0.740) but may contribute to disease onset and aggressiveness. 
      IL-18-607 CC genotype was significantly associated with higher tumor size (p = 
      0.001), grade (p = 0.030), T (p = 0.001), M (p = 0.012), and stage (p = 0.002). 
      IL-18-103 GG genotype was correlated with higher tumor size (p = 0.036), grade (p 
      = 0.017), T (p = 0.026), and stage (p = 0.011). The Cox proportional hazard model 
      showed that nuclear grade and stage grouping were independent prognostic factors 
      but IL-18 polymorphism was not. Polymorphism variants in the IL-18 gene 
      (IL-18-607 and IL-18-137) may be associated with a worse prognosis for RCC. High 
      levels of IL-18 production may play a major role in the growth, invasion and 
      metastasis of renal cancer.
CI  - (c) 2010 American Society for Histocompatibility and Immunogenetics. Published by 
      Elsevier Inc. All rights reserved.
FAU - Saenz-Lopez, Pablo
AU  - Saenz-Lopez P
AD  - Servicio de Analisis Clinicos e Inmunologia, Hospital Universitario Virgen de 
      las, Nieves, Granada, Spain.
FAU - Carretero, Rafael
AU  - Carretero R
FAU - Vazquez, Fernando
AU  - Vazquez F
FAU - Martin, Javier
AU  - Martin J
FAU - Sanchez, Elena
AU  - Sanchez E
FAU - Tallada, Miguel
AU  - Tallada M
FAU - Garrido, Federico
AU  - Garrido F
FAU - Cozar, Jose Manuel
AU  - Cozar JM
FAU - Ruiz-Cabello, Francisco
AU  - Ruiz-Cabello F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100112
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Renal Cell/*diagnosis/epidemiology/*genetics/pathology/physiopathology
MH  - Disease Progression
MH  - Female
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Interleukin-18/*genetics
MH  - Kidney Neoplasms/*diagnosis/epidemiology/*genetics/pathology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Polymorphism, Genetic
MH  - Prognosis
MH  - Spain
MH  - Survival Analysis
EDAT- 2009/12/08 06:00
MHDA- 2010/09/08 06:00
CRDT- 2009/12/08 06:00
PHST- 2009/07/16 00:00 [received]
PHST- 2009/11/13 00:00 [revised]
PHST- 2009/11/24 00:00 [accepted]
PHST- 2009/12/08 06:00 [entrez]
PHST- 2009/12/08 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
AID - S0198-8859(09)00650-8 [pii]
AID - 10.1016/j.humimm.2009.11.010 [doi]
PST - ppublish
SO  - Hum Immunol. 2010 Mar;71(3):309-13. doi: 10.1016/j.humimm.2009.11.010. Epub 2010 
      Jan 12.